119 related articles for article (PubMed ID: 16862579)
1. Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys.
Kordower JH; Kanaan NM; Chu Y; Suresh Babu R; Stansell J; Terpstra BT; Sortwell CE; Steece-Collier K; Collier TJ
Ann Neurol; 2006 Aug; 60(2):264-8. PubMed ID: 16862579
[TBL] [Abstract][Full Text] [Related]
2. Lack of nigrostriatal pathology in a rat model of proteasome inhibition.
Manning-Boğ AB; Reaney SH; Chou VP; Johnston LC; McCormack AL; Johnston J; Langston JW; Di Monte DA
Ann Neurol; 2006 Aug; 60(2):256-60. PubMed ID: 16862576
[TBL] [Abstract][Full Text] [Related]
3. Reproducible nigral cell loss after systemic proteasomal inhibitor administration to rats.
Zeng BY; Bukhatwa S; Hikima A; Rose S; Jenner P
Ann Neurol; 2006 Aug; 60(2):248-52. PubMed ID: 16862581
[TBL] [Abstract][Full Text] [Related]
4. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
McNaught KS; Perl DP; Brownell AL; Olanow CW
Ann Neurol; 2004 Jul; 56(1):149-62. PubMed ID: 15236415
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition and Parkinson's disease modeling.
Bové J; Zhou C; Jackson-Lewis V; Taylor J; Chu Y; Rideout HJ; Wu DC; Kordower JH; Petrucelli L; Przedborski S
Ann Neurol; 2006 Aug; 60(2):260-4. PubMed ID: 16862585
[TBL] [Abstract][Full Text] [Related]
6. The proteasomal inhibition model of Parkinson's disease: "Boon or bust"?
Beal F; Lang A
Ann Neurol; 2006 Aug; 60(2):158-61. PubMed ID: 16862578
[No Abstract] [Full Text] [Related]
7. Effects of systemic PSI administration on catecholaminergic cells in the brain, adrenal medulla and carotid body in Wistar rats.
Hawlitschka A; Haas SJ; Schmitt O; Weiss DG; Wree A
Brain Res; 2007 Oct; 1173():137-44. PubMed ID: 17850771
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibitor model of Parkinson's disease in mice is confounded by neurotoxicity of the ethanol vehicle.
Landau AM; Kouassi E; Siegrist-Johnstone R; Desbarats J
Mov Disord; 2007 Feb; 22(3):403-7. PubMed ID: 17230468
[TBL] [Abstract][Full Text] [Related]
9. The effects of dose and route of administration of PSI on behavioural and biochemical indices of neuronal degeneration in the rat brain.
Bukhatwa S; Zeng BY; Rose S; Jenner P
Brain Res; 2010 Oct; 1354():236-42. PubMed ID: 20678493
[TBL] [Abstract][Full Text] [Related]
10. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats.
Miwa H; Kubo T; Suzuki A; Kondo T
Neurosci Lett; 2006 Jun; 401(1-2):146-9. PubMed ID: 16600504
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition in medaka brain induces the features of Parkinson's disease.
Matsui H; Ito H; Taniguchi Y; Inoue H; Takeda S; Takahashi R
J Neurochem; 2010 Oct; 115(1):178-87. PubMed ID: 20649841
[TBL] [Abstract][Full Text] [Related]
12. Proteasomal inhibition causes loss of nigral tyrosine hydroxylase neurons.
Schapira AH; Cleeter MW; Muddle JR; Workman JM; Cooper JM; King RH
Ann Neurol; 2006 Aug; 60(2):253-5. PubMed ID: 16862591
[TBL] [Abstract][Full Text] [Related]
13. Treadmill exercise suppresses nigrostriatal dopaminergic neuronal loss in 6-hydroxydopamine-induced Parkinson's rats.
Yoon MC; Shin MS; Kim TS; Kim BK; Ko IG; Sung YH; Kim SE; Lee HH; Kim YP; Kim CJ
Neurosci Lett; 2007 Aug; 423(1):12-7. PubMed ID: 17644250
[TBL] [Abstract][Full Text] [Related]
14. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
15. Proteasome inhibitor-induced model of Parkinson's disease.
McNaught KS; Olanow CW
Ann Neurol; 2006 Aug; 60(2):243-7. PubMed ID: 16862580
[TBL] [Abstract][Full Text] [Related]
16. Identification and kainic acid-induced up-regulation of low-affinity p75 neurotrophin receptor (p75NTR) in the nigral dopamine neurons of adult rats.
Wang YQ; Bian GL; Bai Y; Cao R; Chen LW
Neurochem Int; 2008 Sep; 53(3-4):56-62. PubMed ID: 18639597
[TBL] [Abstract][Full Text] [Related]
17. Chronic systemic treatment with a high-dose proteasome inhibitor in mice produces akinesia unrelated to nigrostriatal degeneration.
Shin M; Jan C; Jacquard C; Jarraya B; Callebert J; Launay JM; Hantraye P; Remy P; Palfi S; Brouillet E
Neurobiol Aging; 2011 Nov; 32(11):2100-2. PubMed ID: 20018410
[TBL] [Abstract][Full Text] [Related]
18. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
19. Chronic inhalation of rotenone or paraquat does not induce Parkinson's disease symptoms in mice or rats.
Rojo AI; Cavada C; de Sagarra MR; Cuadrado A
Exp Neurol; 2007 Nov; 208(1):120-6. PubMed ID: 17880941
[TBL] [Abstract][Full Text] [Related]
20. Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease.
Bouchez G; Sensebé L; Vourc'h P; Garreau L; Bodard S; Rico A; Guilloteau D; Charbord P; Besnard JC; Chalon S
Neurochem Int; 2008 Jun; 52(7):1332-42. PubMed ID: 18372079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
